UNSPSC 51161716: Doxapram

This classification denotes a cns stimulant with the molecular formula C24H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94F3830Q73, chemically known as 2-pyrrolidinone, 1-ethyl-4- (2-morpholinoethyl)-3,3-diphenyl-, monohydrochloride but generally known as doxapram, which bears US NIH Compound Identifier 3156. European Medicines Agency schedules Doxapram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06382MIG.

UNSPSC 51161716 Doxapram is a Commodity code that in practice spans a broader range of pharmaceutical procurement than the code name alone suggests. State and local governments buying under this code are purchasing emergency pharmaceuticals, community health supplies, on-site pharmacy services, and multi-source generic medications through cooperative purchasing arrangements. Recent opportunities show counties and state health agencies procuring naloxone and drug deactivation systems for community health initiatives, establishing on-site pharmacy services at government health clinics, and joining multistate cooperative agreements for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers. The issuing bodies include county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP). These jurisdictions range from small county health clinics to state-level pharmacy benefit programs serving multiple participating entities.

Recent activity concentrates in Florida, Georgia, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2026. Hall County, Georgia issued RFQ/P #47-010 on May 4, 2026, to procure on-site pharmacy services for its government health clinic in Gainesville, serving approximately 3,005 eligible individuals across multiple insurance plans, with responses due June 4, 2026. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Department of Administration's MMCAP issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, leveraging authorized wholesalers and serving multiple participating state and local facilities including Oregon. Cooperative purchasing vehicles and multistate agreements feature prominently in the recent activity, particularly for cost containment and standardized procurement across jurisdictions.